Compare · ABCM vs RVMD
ABCM vs RVMD
Side-by-side comparison of Abcam plc (ABCM) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCM and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $27.92B, about 6.1x ABCM ($4.59B).
- RVMD has hit the wire 22 times in the past 4 weeks while ABCM has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 3 for ABCM).
- Company
- Abcam plc
- Revolution Medicines Inc.
- Price
- $23.98+0.00%
- $139.60-3.20%
- Market cap
- $4.59B
- $27.92B
- 1M return
- -
- +41.57%
- 1Y return
- -
- +242.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 0
- 22
- Recent ratings
- 3
- 25
Abcam plc
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ABCM
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form 15-12G filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form POSASR filed by Abcam plc
- SEC Form SC 13D/A filed by Abcam plc (Amendment)
- SEC Form 25-NSE filed by Abcam plc
- Danaher Completes Acquisition of Abcam
Latest RVMD
- Officer Mancini Anthony exercised 3,120 shares at a strike of $33.62 and sold $413,129 worth of shares (3,120 units at $132.41) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
- SEC Form DEFA14A filed by Revolution Medicines Inc.
- SEC Form DEF 14A filed by Revolution Medicines Inc.
- Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
- SEC Form 4 filed by Goldsmith Mark A
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares